ESR14 – Moving on to the next adventure

“If you are brave enough to say goodbye, life will reward you with a new hello!” – Paulo Coelho – Our ESR14 Sonia Leonardelli spun the Postdoc Fortune Wheel and took a chance! She hit the jackpot with a new job! Sonia recently has been awarded by the MildredRead More

Introducing Dr Sonia Leonardelli

December 2019 Essen, Germany 2019 ended with a successful PhD defense! Congratulations to Dr. Sonia Leonardelli for defending her PhD dissertation entitled “Genomic and non-genomic alterations in melanoma contributing to disease progression and therapy resistance”. During her PhD Sonia (ESR14; University Hospital of Essen) focused on understanding the mechanismsRead More

Unite and Conquer Cancer

ASCO 2019 The ASCO (American Society of Clinical Oncology) organization provides an excellent platform for education of oncology professionals, promoting cancer research and advocating patients who suffer from cancer. Every year, the ASCO Annual Meeting takes place at the McCormick Place in Chicago, Illinois with the goal of conqueringRead More

First EACR-ESMO joint conference on Liquid Biopsies 2019 highlights

The first EACR-ESMO joint conference on Liquid Biopsies conference took place at the historic Centro Congressi Giovannia XXIII in Bergamo, Italy from 15-17 May 2019. I was delighted that I could attend my first liquid biopsy meeting ever, especially because I was one of the recipients of the EACR-WorldwideRead More

MELGEN at the European Researchers’ Night 2018!

European Researchers’ Night is an annual open science initiative that occurs in September which is dedicated to bringing popular science and the work of scientists into the general public. Over the course of two days, there are several events that are organized across Europe which help to interact andRead More

Latest melanoma drug approvals: adjuvant dabrafenib plus trametinib

New drug combination: adjuvant dabrafenib plus trametinib for BRAF-mutant stage III melanoma The European Commission approved the combination of dabrafenib plus trametinib (Tafinlar® and Mekinist® by Novartis) for the adjuvant therapy of complete surgically resected stage III melanoma patients with BRAFV600 mutation. The dual targeting of the hyper-activated MAPKRead More

Liquid biopsy: a non-invasive alternative to tissue biopsy

ctDNA as a liquid biopsy for real-time therapy prediction Here is a short video that summarizes my liquid biopsy research project employing circulating cell-free tumor DNA (ctDNA for short) . The goal of my project is to validate blood-based biomarkers in melanoma. When normal and cancer cells die theyRead More

Latest melanoma drug approvals: encorafenib plus binimetinib

New drug combination: encorafenib plus binimetinib for BRAF-mutant metastatic melanoma Another milestone in the treatment of BRAFV600-mutant metastatic melanoma was marked by the newly approved drug combination of encorafenib plus binimetinib [Braftovi and Mektovi, by Array BioPharma Inc; approved by U.S. Food & Drug Administration (FDA) on June 27,Read More